Key Points
- Doximity director Timothy Cabral sold 10,721 shares for $375,235 at an average of $35 each, reducing his direct stake by 57% to 8,084 shares. The sale was made under a pre-arranged Rule 10b5-1 plan.
- Doximity reported quarterly earnings of $0.36 per share, beating the $0.19 analyst consensus; revenue rose 3.6% year over year to $174.54 million.
- Analyst views were mixed: the stock had a consensus “Hold” rating and a $30.45 price target, while Canaccord raised its target to $40 and maintained a Buy rating.
Doximity, Inc. (NYSE:DOCS - Get Free Report) Director Timothy Cabral sold 10,721 shares of the company's stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $35.00, for a total transaction of $375,235.00. Following the completion of the sale, the director directly owned 8,084 shares in the company, valued at $282,940. This trade represents a 57.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Doximity Price Performance
DOCS stock opened at $33.02 on Tuesday. The company's 50 day simple moving average is $29.22 and its 200-day simple moving average is $25.47. The firm has a market capitalization of $5.89 billion, a PE ratio of 45.87, a P/E/G ratio of 27.12 and a beta of 1.29. Doximity, Inc. has a 12 month low of $17.15 and a 12 month high of $55.96.
Doximity (NYSE:DOCS - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.17. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The business had revenue of $174.54 million during the quarter. During the same period last year, the business earned $0.45 earnings per share. The company's revenue for the quarter was up 3.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Doximity, Inc. will post 0.74 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on DOCS. Canaccord Genuity Group boosted their price target on Doximity from $36.00 to $40.00 and gave the stock a "buy" rating in a report on Friday. Freedom Capital lowered Doximity from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 8th. Truist Financial increased their price objective on Doximity from $19.00 to $24.00 and gave the company a "hold" rating in a research note on Thursday, August 13th. Raymond James Financial reiterated an "outperform" rating and set a $38.00 price objective on shares of Doximity in a research report on Friday, October 16th. Finally, Evercore set a $35.00 target price on shares of Doximity in a research note on Tuesday, September 29th. Eight analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $30.45.
Check Out Our Latest Report on DOCS
Institutional Trading of Doximity
A number of hedge funds have recently bought and sold shares of DOCS. Carmignac Gestion raised its holdings in Doximity by 127.8% in the 1st quarter. Carmignac Gestion now owns 4,311,997 shares of the company's stock valued at $100,480,000 after acquiring an additional 2,418,971 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Doximity during the third quarter worth $28,858,000. Renaissance Technologies LLC grew its position in shares of Doximity by 29.4% in the first quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company's stock valued at $71,292,000 after purchasing an additional 694,300 shares during the period. Wellington Management Group LLP grew its position in shares of Doximity by 24.7% in the second quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company's stock valued at $65,022,000 after purchasing an additional 621,464 shares during the period. Finally, Amundi grew its position in shares of Doximity by 9,956.5% in the first quarter. Amundi now owns 569,095 shares of the company's stock valued at $13,260,000 after purchasing an additional 563,436 shares during the period. Institutional investors and hedge funds own 87.19% of the company's stock.
Trending Headlines about Doximity
Here are the key news stories impacting Doximity this week:
- Positive Sentiment: Analysts raised Doximity price targets to $40 and $34, and Needham reiterated its Buy rating, signaling continued optimism from some analysts. Read More.; Read More.; Read More..
- Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000 under a pre-arranged Rule 10b5-1 plan. The planned nature of the sale may temper its significance, though insider selling can still concern investors. Read More..
- Negative Sentiment: Several law firms publicized a securities class action against Doximity and a November 16 lead-plaintiff deadline. The suit covers investors who bought shares from August 8, 2024, through May 13, 2026, and alleges the company misrepresented or failed to disclose issues involving revenue growth, market share, slowing sales, declining net income, and pharmaceutical customers’ advertising budgets. These are allegations, not established findings; the litigation could add uncertainty and reputational risk. Read More..
Doximity Company Profile
(
Get Free Report)
Doximity, Inc operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals.
The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.
Founded in 2010, Doximity primarily serves the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
